Edwards, St. Jude Pursue Opposite Pricing Strategies For New Tissue Valves
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical does not expect a significant price premium for its BioCor and Epic porcine tissue heart valves upon U.S. approval, anticipated in 2004 and 2006, respectively, the firm says
You may also be interested in...
St. Jude ICD, Tissue Valve Differentiation Will Fall To Incoming CEO Starks
Incoming Chairman and CEO Daniel Starks will direct St. Jude Medical's efforts to catch up with established players in the tissue valve and cardiac resynchronization therapy defibrillator markets
St. Jude ICD, Tissue Valve Differentiation Will Fall To Incoming CEO Starks
Incoming Chairman and CEO Daniel Starks will direct St. Jude Medical's efforts to catch up with established players in the tissue valve and cardiac resynchronization therapy defibrillator markets
MCRI On-X Looks To Revive Mechanical Heart Valve Market
Preliminary data demonstrating whether MCRI's On-X mechanical heart valve can be used with minimal anti-coagulation therapy will be available in the second or third quarter of 2004, the firm says